PrinterPrezz, a US-based developer of medical-focused 3D printing technology, closed a $16m series A round yesterday that included Solvay Ventures, the corporate venturing arm of chemicals producer Solvay.
The round was led by investment firm D.One Vision Management’s DOV Singularity Fund and also featured Berkeley Catalyst Fund, the venture capital unit aligned to University of California (UC) Berkeley, as well as VC firm Boutique Venture Partners.
Founded in 2018, PrinterPrezz combines 3D printing, design and prototyping technology with its nanotechnology and semiconductor expertise to develop and manufacture specialised medical devices for partners. It recently secured regulatory approval in the US for six of its devices
Shri Shetty, chief executive of PrinterPrezz, said: “We believe that the future of medical device development is in the joining of novel materials with proprietary technology.
“PrinterPrezz continues to offer opportunities for innovative medical device companies to leverage our infrastructure and know-how to speed their time-to-market.”
The original version of this article appeared on our sister site, Global University Venturing.